Predict your next investment

Corporation
HEALTHCARE | Drug Development
glpg.com, galadeno.com

See what CB Insights has to offer

Founded Year

1999

Stage

IPO | IPO

Total Raised

$27.78M

Date of IPO

5/6/2005

About Galapagos Genomics

Developer of a functional genomics platform that consists of the construction and screening of adenoviral knock-in and knock-down libraries for the discovery and validation of novel drug targets and therapeutic genes. The screening of the libraries is performed in human cell-based and phenotypic functional assays. Both the construction and the screening of the libraries are set up in a high-throughput, automated and arrayed format. The phenotypic selection libraries are used both for internal discovery activities as well as in collaboration agreements with partners. The company is focused on the rapid identification and validation of disease modifying drug targets by functional screening in human disease models. Research activities encompass the internal programs in osteoporosis, rheumatoid arthritis, osteoarthritis, and Alzheimer's disease, as well as partnerships with pharmaceutical, nutraceutical, and biotech companies. Proprietary targets resulting from internal programs are used for the development of drugs in core disease areas, combined with selected out-licensing and partnering of projects during development.

Galapagos Genomics Headquarter Location

Industriepark Mechelen Noord Generaal De Wittelaan L11 A3

Mechelen, 2800,

Belgium

32 153 429 00

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.